Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cadrenal Therapeutics, Inc. (CVKD)
NASDAQ:CVKD
RESEARCH TOOLSreports
Holding CVKD?
Track your performance easily
CVKD Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$5.40 - $32.55
Previous Close$16.45
Volume58.36K
Average Volume (3M)71.39K
Market Cap
$29.32M
Enterprise Value$29.32M
Total Cash (Recent Filing)$0.00
Total Debt (Recent Filing)$2.23K
Price to Earnings (P/E)―
Beta1.00
Next Earnings
Mar 17, 2025EPS Estimate
-$2.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.30
Shares Outstanding1,658,771
10 Day Avg. Volume122,747
30 Day Avg. Volume71,388
Standard Deviation0.45
R-Squared0.01
Alpha0.00729
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)7.99
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-2.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-133.23
Enterprise Value/Ebitda-6.85
Forecast
1Y Price Target
$38.50Price Target Upside138.39% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Cadrenal Therapeutics, Inc. News
PremiumCompany Announcements
Cadrenal Therapeutics Advances Tecarfarin Development
PremiumCompany Announcements
Cadrenal Therapeutics Raises $5.1 Million for Tecarfarin
PremiumCompany Announcements
Cadrenal Therapeutics Unveils Phase 3 Trials and Market Strategy
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CVKD FAQ
What was Cadrenal Therapeutics, Inc.’s price range in the past 12 months?
Cadrenal Therapeutics, Inc. lowest stock price was $5.40 and its highest was $32.55 in the past 12 months.
What is Cadrenal Therapeutics, Inc.’s market cap?
Currently, no data Available
When is Cadrenal Therapeutics, Inc.’s upcoming earnings report date?
Cadrenal Therapeutics, Inc.’s upcoming earnings report date is Mar 17, 2025 which is in 80 days.
How were Cadrenal Therapeutics, Inc.’s earnings last quarter?
Cadrenal Therapeutics, Inc. released its earnings results on Nov 07, 2024. The company reported -$2.18 earnings per share for the quarter, missing the consensus estimate of -$1.927 by -$0.253.
Is Cadrenal Therapeutics, Inc. overvalued?
According to Wall Street analysts Cadrenal Therapeutics, Inc.’s price is currently Undervalued.
Does Cadrenal Therapeutics, Inc. pay dividends?
Cadrenal Therapeutics, Inc. does not currently pay dividends.
What is Cadrenal Therapeutics, Inc.’s EPS estimate?
Cadrenal Therapeutics, Inc.’s EPS estimate is -$2.02.
How many shares outstanding does Cadrenal Therapeutics, Inc. have?
Cadrenal Therapeutics, Inc. has 1,782,486 shares outstanding.
What happened to Cadrenal Therapeutics, Inc.’s price movement after its last earnings report?
Cadrenal Therapeutics, Inc. reported an EPS of -$2.18 in its last earnings report, missing expectations of -$1.927. Following the earnings report the stock price went up 2.388%.
Which hedge fund is a major shareholder of Cadrenal Therapeutics, Inc.?
Currently, no hedge funds are holding shares in CVKD
---
Company Description
Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics Inc is focused on developing a novel therapy with orphan drug indication, tecarfarin, for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (on dialysis) and atrial fibrillation (irregular heartbeat) or AFib. Tecarfarin is an anticoagulant designed using a drug design process that targets a different pathway than most commonly prescribed drugs for the treatment of thrombosis and AFib.
---
CVKD Stock 12 Month Forecast
Average Price Target
$38.50
▲(138.39% Upside)
Technical Analysis
Aclaris Therapeutics
―
Clearside Biomedical
―
Eton Pharmaceuticals
―
Achieve Life Sciences
―
Best Analysts Covering CVKD
1 Year
1 Year Success Rate
5/6 ratings generated profit
1 Year Average Return
+93.87%
reiterated a buy rating 2 months ago
Copying Joseph Pantginis's trades and holding each position for 1 Year would result in 83.33% of your transactions generating a profit, with an average return of +93.87% per trade.
---